Abstract Library

#4660 Clinical significance of interval imaging in patients with well-differentiated neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)

Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.

Conference:

Presenting Author:

Authors: Grewal U, Patel R, Chandasekharan C,

Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,

#3203 The efficacy of above-label doses of long-acting somatostatin analogues for the management of patients with gastroenteropancreatic tumors

Introduction: Above-label doses of long-acting somatostatin analogues (SSAs) are increasingly used for the control of secretory syndrome or as anti-proliferative treatment in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Tsoli M, Daskalakis K, Koumarianou A, Kolomodi D, Anagnostou E,

Keywords: neuroendocrine tumor, somatostatin analogues, medical treatment,

#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy

Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Strosberg J

Authors: Strosberg J, Cives M, Brelsford M, Black M, Meeker A,

Keywords: ki67, MGMT, ALT, chromosomal instability, temozolomide, capecitabine, pNET,

#826 Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors

Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Cheng Y, Sun Z, Bai C, Ying H, Meng C,

Keywords: CgA change, radiographic response, nonfunctioning NETs,